Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226778 · ClinicalTrials.gov registry record · Phase 1
Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations
A Phase 1 study of Obesity and Overweight, sponsored by Amgen.
- Active
- Registry status
- Phase 1
- Development phase
- 348
- Enrollment target
- 4
- Study locations
NCT07226778: Active Phase 1 study of Obesity and Overweight, sponsored by Amgen.
NCT07226778 is a Phase 1 study of Obesity and Overweight that is active but no longer recruiting, run by Amgen. The registered enrollment target is 348 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (58% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226778, a Phase 1 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 348 participants
- Enrollment target
- 4
- Study locations
Study Summary
The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.
Conditions Studied
Interventions
- DRUG Maridebart Cafraglutide
Study Locations (4)
California
- Anaheim Clinical Trials - Anaheim
Florida
- Fortrea Clinical Research Unit - Daytona Beach - Daytona Beach
Texas
- Fortrea Clinical Research Unit - Dallas - Dallas
Wisconsin
- Fortrea Clinical Research Unit Inc. - Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2025-10-10 |
| Est. Completion | 2026-05-28 |
| Phase | Phase 1 |
What the registry record for NCT07226778 still lists
NCT07226778 is an interventional study that assigns participants to a tested intervention. The registered 348 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (58% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Maridebart Cafraglutide is the first listed.
NCT07226778 reports a single indexed study location in California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07226778 about?
NCT07226778 is a clinical study titled "Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations". The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.
What is the current status of trial NCT07226778?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 348 participants. The study started on 2025-10-10. Estimated completion is 2026-05-28.
What conditions does trial NCT07226778 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT07226778?
The interventions under investigation include: Maridebart Cafraglutide (DRUG).
Who is sponsoring clinical trial NCT07226778?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226778 being conducted?
This trial has 4 study locations across California, Florida, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07226778's enrollment target sits among peer trials
348 189th of 1053 higher than 865 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041479 · 348 participants · Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
- NCT04530565 · 348 participants · Phase 3
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- NCT05428735 · 348 participants · NA
The DRAGON 2 Trial
- NCT05787379 · 348 participants · NA
Care for Veterans Post-COVID-19
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI